Skip to main content

Finch Therapeutics Group, Inc. (FNCH)

NASDAQ: FNCH · Delayed Price · USD
14.70 0.95 (6.91%)
Sep 17, 2021 4:00 PM EDT - Market closed
Market Cap697.50M
Revenue (ttm)9.96M
Net Income (ttm)n/a
Shares Out47.45M
EPS (ttm)-2.68
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume77,772
Open13.51
Previous Close13.75
Day's Range13.30 - 14.70
52-Week Range11.56 - 22.50
Betan/a
Analystsn/a
Price Target29.67 (+101.8%)
Est. Earnings DateNov 9, 2021

About FNCH

Finch Therapeutics Group, Inc., a clinical-stage microbiome therapeutics company, develops a novel class of orally administered biological drugs in the United States. The company's lead candidate is CP101, an orally administered microbiome capsule that has completed Phase II clinical trial for the treatment of patients with recurrent Clostridioides difficile infection, as well as for the treatment of chronic hepatitis B virus. It is also developing FIN-211, an orally administered enriched consortia product candidate for use in the treatment of ...

IndustryBiotechnology
IPO DateMar 19, 2021
Employees186
Stock ExchangeNASDAQ
Ticker SymbolFNCH
Full Company Profile

Financial Performance

In 2020, FNCH's revenue was $7.72 million, a decrease of -23.98% compared to the previous year's $10.15 million. Losses were -$39.34 million, 89.6% more than in 2019.

Financial Statements

News

Finch Therapeutics to Present at the H.C. Wainwright 23rd Annual Global Investment Conference

SOMERVILLE, Mass., Sept. 07, 2021 (GLOBE NEWSWIRE) -- Finch Therapeutics Group, Inc. (“Finch” or “Finch Therapeutics”) (Nasdaq: FNCH), a clinical-stage microbiome therapeutics company leveraging its Hum...

1 week ago - GlobeNewsWire

Finch Therapeutics Reports Second Quarter 2021 Financial Results and Provides Business Update

SOMERVILLE, Mass., Aug. 10, 2021 (GLOBE NEWSWIRE) -- Finch Therapeutics Group, Inc. (“Finch” or “Finch Therapeutics”) (Nasdaq: FNCH), a clinical-stage microbiome therapeutics company leveraging its Huma...

1 month ago - GlobeNewsWire

Finch Therapeutics Announces Takeda to Accelerate Leadership Role in FIN-524 Ulcerative Colitis Development Program

SOMERVILLE, Mass., Aug. 10, 2021 (GLOBE NEWSWIRE) -- Finch Therapeutics Group, Inc. (“Finch” or “Finch Therapeutics”) (Nasdaq: FNCH), a clinical-stage microbiome therapeutics company leveraging its Huma...

1 month ago - GlobeNewsWire

Finch Therapeutics Added to Russell 2000 and Russell 3000 Indexes

SOMERVILLE, Mass., June 28, 2021 (GLOBE NEWSWIRE) -- Finch Therapeutics Group, Inc. (“Finch” or “Finch Therapeutics”) (Nasdaq: FNCH), a clinical-stage microbiome therapeutics company leveraging its Huma...

2 months ago - GlobeNewsWire

Finch Therapeutics to Present at Upcoming Virtual Investor Conferences

SOMERVILLE, Mass., May 28, 2021 (GLOBE NEWSWIRE) -- Finch Therapeutics Group, Inc. (“Finch” or “Finch Therapeutics”) (Nasdaq: FNCH), a clinical-stage microbiome therapeutics company leveraging its Human...

3 months ago - GlobeNewsWire

Finch Therapeutics Reports First Quarter 2021 Financial Results and Provides Business Updates

SOMERVILLE, Mass., May 13, 2021 (GLOBE NEWSWIRE) -- Finch Therapeutics Group, Inc. (“Finch” or the “Company”) (Nasdaq: FNCH), a clinical-stage microbiome therapeutics company leveraging its Human-First ...

4 months ago - GlobeNewsWire

Finch Therapeutics to Participate in the BofA Securities 2021 Virtual Health Care Conference

SOMERVILLE, Mass., May 06, 2021 (GLOBE NEWSWIRE) -- Finch Therapeutics Group, Inc. (“Finch” or “Finch Therapeutics”) (Nasdaq: FNCH), a clinical-stage microbiome therapeutics company leveraging its Human...

4 months ago - GlobeNewsWire

Finch Therapeutics Appoints Susan E. Graf to Board of Directors

SOMERVILLE, Mass., April 27, 2021 (GLOBE NEWSWIRE) -- Finch Therapeutics Group, Inc. (“Finch” or “Finch Therapeutics”) (Nasdaq: FNCH), a clinical-stage microbiome therapeutics company leveraging its Hum...

4 months ago - GlobeNewsWire

The IPO Market Had A Busy Week

Last week was a busy one for the IPO market with 11 IPOs raising $3 billion, joined by 24 SPACs that brought another $8.4 billion to the table. Chinese IoT platform developer Tuya Inc (NYSE: TUYA) raise...

5 months ago - Benzinga

Finch Therapeutics Announces Pricing of Upsized Initial Public Offering

SOMERVILLE, Mass., March 18, 2021 (GLOBE NEWSWIRE) -- Finch Therapeutics Group, Inc. (“Finch” or “Finch Therapeutics”) (Nasdaq: FNCH), a clinical-stage microbiome therapeutics company leveraging its Hum...

6 months ago - GlobeNewsWire

Microbiome therapy biotech Finch Therapeutics Group files for a $100 million IPO

Finch Therapeutics Group, a Phase 3-ready biotech developing microbiome therapeutics, filed on Friday with the SEC to raise up to $100 million in an initial public offering.

6 months ago - NASDAQ

Finch Therapeutics Group IPO Registration Document (S-1)

Finch Therapeutics Group, Inc. has filed to go public with an IPO on the NASDAQ.

6 months ago - SEC